<DOC>
	<DOCNO>NCT02440893</DOCNO>
	<brief_summary>The study goal understand effect Metformin Corus® CAD ( henceforth `` Corus '' ) pre-diabetic patient medication naive . This study provide data determine Corus gene expression signature different pre-diabetic patient metformin newly prescribe take .</brief_summary>
	<brief_title>Metformin Corus CAD</brief_title>
	<detailed_description>The study goal understand effect Metformin Corus® CAD ( henceforth `` Corus '' ) pre-diabetic patient medication naive . This study provide data determine Corus gene expression signature different pre-diabetic patient metformin newly prescribe take . The primary aim study evaluate whether metformin use pre-diabetic patient prevent progression type II diabetes significant effect gene expression level measure Corus . This prospective study . Subjects enrol participate site applicable inclusion/exclusion criterion meet . The study aim enroll approximately fifty ( 50 ) patient .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>At least 21 year age Any follow : Chest pain syndrome , stable angina , anginal equivalent suggest myocardial ischemia Lowrisk unstable angina , Asymptomatic individual high probability CAD Clinician diagnosis prediabetes , per ADA guideline , metformin therapy prescribed : HgA1C : &gt; 5.7 % &lt; 6.4 % , BMI &gt; 35 kg/m2 Age &lt; 60 yr Prior Gestational Diabetes Mellitus FPG : &gt; 100mg/dl &lt; 126mg/dl OGTT : &gt; 140mg/dl &lt; 200mg/dl Willingness comply metformin therapy , least seven ( 7 ) day ( P.O. , per physician 's dosage discretion ) Willingness maintain drug diary duration study , full followup period ( 7 + 7 day ) Willingness ability provide two ( 2 ) sample Corus ( baseline , 7 ( + 7 ) day post medication start ) Provide write informed consent History current level HbA1C &gt; 6.5 History current prescription metformin diabetic medication History myocardial infarction ( MI ) prior revascularization Current MI acute coronary syndrome ( ACS ) Current New York Heart Association ( NYHA ) class III IV congestive heart failure symptom Current systemic infectious systemic inflammatory condition Subjects currently take steroid , immunosuppressive agent chemotherapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>